Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 10/20 | 0.38 |
| ▸ | CA2 | P00918 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517106 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL517316 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL197507 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL517150 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL674231 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL198030 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2691635 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL497426 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL196434 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 | |
| SCHEMBL517375 | 1.00 | THRB (0.52) | THRBF2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012024592-A2 | COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-23 | — | — | WO | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| US-9156938-B2 | Compositions, methods, and systems comprising fluorous-soluble polymers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-10-13 | — | — | US | disclosed |
| US-8487003-B2 | Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids | CXR BIOSCIENCES LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-20120177578-A1 | COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2012024592-A2 | COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120029079-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| US-7955532-B2 | High performance capsules for electrophoretic displays | SIPIX IMAGING, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| EP-2260842-A2 | Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass | CXR Biosciences Limited (GB) | 2010-12-15 | — | — | EP | disclosed |
| EP-1359906-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LTD (GB) | 2008-05-14 | — | — | EP | disclosed |
| US-20050175639-A1 | Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids | CXR BIOSCIENCES LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20040182711-A1 | Switching rate and resistance to humidity; allows low manufacturing cost because no drying, purification or re-dispersion of the capsules is needed to remove water or undesirable hydrophilic impurities | E INK CORPORATION | 2004-09-23 | — | — | US | disclosed |
| WO-2004068234-A1 | HIGH PERFORMANCE CAPSULES FOR ELECTROPHORETIC DISPLAYS | SIPIX IMAGING, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-1359906-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002066028-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120177578-A1 | COMPOSITIONS, METHODS, AND SYSTEMS COMPRISING FLUOROUS-SOLUBLE POLYMERS | NAF1, PFAS, MALT1 | THRB 3638/4885F2 201/4885PRSS1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.